Cercle’s core product is the Cercle Biomedical Graph™, a platform that ingests and transforms de-identified, unstructured women’s healthcare data into real-time, high-quality insights. The platform acts as a mediator between patient records and LLMs, anonymizing data and ensuring HIPAA and GDPR compliance while removing personal information. Since its November 2023 introduction, the Graph has captured and analyzed more than one billion anonymized patient data points and is used by partners including US Fertility, Boston IVF, and Eurofins Genoma. Cercle says its technology delivers insights at scale and speed without AI hallucinations, improving clinical workflows and business efficiency. The company plans to widen its application beyond the fertility market, expand its global footprint, and advance its LLM offerings. Management emphasizes product and engineering development to connect LLMs to high-quality women’s-health data and deliver secure, accurate, real-time answers for stakeholders. The company is privately held and recently closed a seed financing to support these efforts. Cercle’s platform has not been evaluated by the FDA and is not classified as a medical device.

Total raised

$6M

Funding rounds

1

Latest round

Seed

Latest activity

Sep 2024